Published in Ann Surg on September 01, 1998
Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest (2000) 1.13
Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model. Mol Ther (2003) 1.09
Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest (2002) 1.03
Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis. PLoS Pathog (2010) 1.03
Oncolytic viral therapy for pancreatic cancer: current research and future directions. Oncolytic Virother (2014) 0.95
Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann Surg (2002) 0.93
Inhibitory effect of endostatin expressed by human liver carcinoma SMMC7721 on endothelial cell proliferation in vitro. World J Gastroenterol (2002) 0.92
Oncolytic virotherapy for pancreatic cancer. Expert Rev Mol Med (2011) 0.88
Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice. Cancer Gene Ther (2008) 0.85
Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer. Cancer Gene Ther (2010) 0.85
The competitive dynamics between tumor cells, a replication-competent virus and an immune response. J Math Biol (2005) 0.83
Analysis of a model of a virus that replicates selectively in tumor cells. J Math Biol (2003) 0.82
Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia (2002) 0.82
Oncolytic viruses in the treatment of bladder cancer. Adv Urol (2012) 0.78
Oncolytic virotherapy for ovarian cancer. Oncolytic Virother (2012) 0.77
Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment. World J Gastroenterol (2008) 0.75
The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res (1993) 2.54
Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst (1998) 2.44
Ganciclovir. N Engl J Med (1996) 2.19
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther (1997) 1.26
Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci U S A (1995) 1.15
Surgical treatment of colorectal metastases to the liver. CA Cancer J Clin (1995) 1.15
Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res (1995) 1.13
Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci U S A (1996) 1.10
Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat Genet (1995) 1.09
Immune system in suicide-gene therapy. Lancet (1997) 1.06
In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res (1993) 1.06
The TMC Worldwide Gene Therapy Enrollment Report, end 1996. Hum Gene Ther (1997) 1.05
Invasive therapy of metastatic colorectal cancer to the liver. Surg Clin North Am (1997) 1.03
Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg (1996) 1.02
Histochemical staining following LacZ gene transfer underestimates transfection efficiency. Hum Gene Ther (1997) 0.98
The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J Surg Res (1997) 0.85
Bystander effects in enzyme/prodrug gene therapy. Hum Gene Ther (1997) 0.83
Gene therapy of cancer. Lancet (1997) 0.83
Gene therapy for liver tumors. Surg Oncol Clin N Am (1996) 0.81
The potential applications of gene transfer in the treatment of patients with cancer: a concise review. Cancer Invest (1996) 0.80
Diagnostic criteria for schwannomatosis. Neurology (2005) 3.41
In vivo magnetic resonance imaging of transgene expression. Nat Med (2000) 3.35
Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer (2000) 2.59
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 2.42
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A (1998) 2.29
Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol (1998) 2.17
Surgical management of phyllodes tumors. Arch Surg (1999) 2.16
Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther (1998) 2.13
Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis (2010) 2.00
Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol (2011) 1.98
Simulated brain tumor growth dynamics using a three-dimensional cellular automaton. J Theor Biol (2000) 1.94
Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg (1999) 1.92
Pattern of self-organization in tumour systems: complex growth dynamics in a novel brain tumour spheroid model. Cell Prolif (2001) 1.86
Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int J Tuberc Lung Dis (2008) 1.85
Isolation and characterization of cDNA clones to mouse macrophage and human endothelial cell tissue transglutaminases. J Biol Chem (1991) 1.60
Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst (1998) 1.60
Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol (2000) 1.54
Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol (2014) 1.53
Ablation of liver tumors using percutaneous RF therapy. AJR Am J Roentgenol (1998) 1.48
An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol (2001) 1.46
Rapid detection and identification of Candida, Aspergillus, and Fusarium species in ocular samples using nested PCR. J Clin Microbiol (2000) 1.46
Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther (2001) 1.45
Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol (1999) 1.43
Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J (2000) 1.41
Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther (2003) 1.31
Measuring transferrin receptor gene expression by NMR imaging. Biochim Biophys Acta (1998) 1.31
Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther (2006) 1.29
Attitudes and opinions toward surgical research. A survey of surgical residents and their chairpersons. Ann Surg (1996) 1.28
Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res (1999) 1.27
Minimal-access surgery for staging of malignant melanoma. Arch Surg (1995) 1.27
MicroRNAs and glioblastoma; the stem cell connection. Cell Death Differ (2009) 1.27
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther (1997) 1.26
Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy. Clin Exp Immunol (2006) 1.21
Experimental photoimmunotherapy of hepatic metastases of colorectal cancer with a 17.1A chlorin(e6) immunoconjugate. Cancer Res (2000) 1.20
B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J Virol (1999) 1.18
Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res (1994) 1.15
Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer (1999) 1.15
An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol (1998) 1.14
Role and regulation of expression of 92-kDa type-IV collagenase (MMP-9) in 2 invasive squamous-cell-carcinoma cell lines of the oral cavity. Int J Cancer (1993) 1.13
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res (2001) 1.12
Cellular automaton of idealized brain tumor growth dynamics. Biosystems (2000) 1.10
Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders. Clin Exp Immunol (2006) 1.09
Surgical treatment and other regional treatments for colorectal cancer liver metastases. Oncologist (1999) 1.06
Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene (2008) 1.06
Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg (2000) 1.06
Emergence of a subpopulation in a computational model of tumor growth. J Theor Biol (2000) 1.06
Stereotactic radiofrequency thermal cingulotomy for obsessive compulsive disorder. J Neuropsychiatry Clin Neurosci (1990) 1.06
Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev (2010) 1.06
An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J (2000) 1.06
Multimodality management of Merkel cell carcinoma. Arch Surg (1999) 1.04
Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther (1998) 1.04
Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum Gene Ther (1994) 1.03
Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am J Pathol (1995) 1.03
Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg (1996) 1.02
Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther (1994) 1.02
Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Hum Gene Ther (1996) 1.02
Glutamine as a regulator of DNA and protein biosynthesis in human solid tumor cell lines. Ann Surg (1996) 1.01
Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells. Gene Ther (1995) 1.01
Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg (1999) 1.00
Primary lymphoma of peripheral nerve: report of four cases. Am J Surg Pathol (2000) 1.00
Progress and prospects: gene therapy clinical trials (part 2). Gene Ther (2007) 1.00
Gene therapy for brain tumors. Brain Pathol (1995) 1.00
Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res (1999) 1.00
Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. J Neurosurg (1999) 0.99
Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res (2001) 0.98
Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther (1994) 0.98
New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther (1998) 0.97
CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas. Oncogene (1995) 0.97
Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res (2001) 0.95
Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. Gene Ther (2004) 0.95
The subtemporal-transpetrous approach for excision of petroclival tumors. Am J Otol (1996) 0.94
Genetic strategies for brain tumor therapy. Cancer Gene Ther (2006) 0.92
CD44s expression in human colon carcinomas influences growth of liver metastases. Int J Cancer (2000) 0.92
Solitary sciatic nerve lymphoma as an initial manifestation of diffuse neurolymphomatosis. Case report and review of the literature. J Neurosurg (2000) 0.92
Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res (2000) 0.92
Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res (1995) 0.91
Keratan sulfate modification of CD44 modulates adhesion to hyaluronate. J Biol Chem (1996) 0.91
Cerebrovascular Biology and the various neural barriers: challenges and future directions. Neurosurgery (1999) 0.91
Surgical management of primary cutaneous melanomas of the hands and feet. Ann Surg (1997) 0.90
Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol (1998) 0.88
Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer (2000) 0.88
Lymphedema after sentinel lymph node biopsy for cutaneous melanoma: a report of 5 cases. Arch Dermatol (2000) 0.88
O-linked glycosylation modifies CD44 adhesion to hyaluronate in colon carcinoma cells. Biochem Biophys Res Commun (1996) 0.88
Involvement of CD44 in matrix metalloproteinase-2 regulation in human melanoma cells. Int J Cancer (1999) 0.87
Growth of human acoustic neuromas, neurofibromas and schwannomas in the subrenal capsule and sciatic nerve of the nude mouse. J Neurooncol (1992) 0.87
Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res (2001) 0.86
Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther (1999) 0.86
Spread of human cancer cells occurs with probabilities indicative of a nongenetic mechanism. Br J Cancer (2005) 0.85
Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum Gene Ther (1996) 0.85
Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice. Cancer Gene Ther (2008) 0.85
Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors. Gene Ther (2006) 0.85
The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J Surg Res (1997) 0.85
Expression of CD44 splicing isoforms in lung cancers: dominant expression of CD44v8-10 in non-small cell lung carcinomas. Int J Oncol (1998) 0.85
Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. Hum Gene Ther (1995) 0.85